




The relative strengths and weaknesses of Lumos Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lumos Pharma INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Lumos Pharma INC is the variable Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 226%, being 13% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	40,035
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,030
Liabilities, Non-Current	303
Other Assets	603
Other Compr. Net Income	9.0
Other Expenses	-29
Other Liabilities	6,000
Other Net Income	2,551
Other Revenues	2,051
Property and Equipment	0
Research and Development	22,096
Selling, General and Administrative Expense	16,569

Output Variable	Value in 1000 USD
Assets	40,638
Liabilities	13,333
Expenses	38,636
Revenues	2,051
Stockholders Equity	27,305
Net Income	-34,034
Comprehensive Net Income	-34,030
BaseVar	48,609
ECR before LimitedLiability	94%
Economic Capital Ratio	226%